• Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 365.12%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.15
▲ +0.11 (5.39%)
Get New Dermira Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DERM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DERM

Analyst Price Target is $10.00
▲ +365.12% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Dermira in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 365.12% upside from the last price of $2.15.

This chart shows the closing price for DERM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Dermira.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/11/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/8/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2022B. RileyLower Target$14.00 ➝ $10.00N/A
2/25/2022Cantor FitzgeraldInitiated CoverageOverweightN/A
12/16/2021Roth CapitalInitiated CoverageBuy$15.00N/A
12/7/2021B. RileyInitiated CoverageBuy$14.00N/A
2/3/2020GuggenheimDowngradeBuy ➝ NeutralLow
1/24/2020Needham & Company LLCDowngradeBuy ➝ HoldLow
1/23/2020HC WainwrightDowngradeBuy ➝ Neutral$18.75Low
1/2/2020SVB LeerinkReiterated RatingOutperformHigh
12/30/2019Needham & Company LLCReiterated RatingBuy$20.00Low
12/12/2019Evercore ISIReiterated RatingBuyHigh
11/5/2019SVB LeerinkLower TargetOutperform$23.00 ➝ $15.00High
10/18/2019Needham & Company LLCReiterated RatingBuy$22.00High
6/6/2019MizuhoUpgradeNeutral ➝ Buy$17.00 ➝ $14.00High
5/8/2019HC WainwrightReiterated RatingBuyHigh
5/3/2019Cantor FitzgeraldReiterated RatingBuy$25.00High
4/23/2019HC WainwrightSet TargetBuy$22.00Low
4/18/2019Cantor FitzgeraldBoost TargetPositive ➝ Overweight$25.00Low
4/2/2019Cantor FitzgeraldReiterated RatingBuy$20.00Medium
3/27/2019HC WainwrightBoost TargetBuy$13.00 ➝ $22.00Low
3/25/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$16.00 ➝ $22.00Low
3/21/2019MizuhoBoost TargetNeutral ➝ Positive$10.00 ➝ $17.00Medium
3/19/2019CitigroupBoost TargetBuy$15.00 ➝ $20.00High
2/22/2019SVB LeerinkInitiated CoverageOutperformHigh
2/14/2019HC WainwrightInitiated CoverageBuy$13.00Low
1/17/2019Raymond JamesUpgradeUnderperform ➝ Market Perform$6.71High
12/28/2018Cantor FitzgeraldSet TargetBuy$20.00High
11/20/2018GuggenheimReiterated RatingBuy ➝ Buy$20.00High
11/7/2018Cantor FitzgeraldReiterated RatingBuy$20.00High
10/2/2018MizuhoReiterated RatingHold$10.00Medium
9/5/2018Cantor FitzgeraldReiterated RatingBuy$20.00Medium
8/6/2018Cantor FitzgeraldSet TargetBuy$20.00Medium
6/29/2018Cantor FitzgeraldSet TargetBuy$20.00Medium
5/25/2018Needham & Company LLCSet TargetBuy$16.00Low
5/24/2018Cantor FitzgeraldSet TargetBuy$20.00High
5/3/2018Cantor FitzgeraldSet TargetBuy$20.00High
4/9/2018Cantor FitzgeraldSet TargetBuy$20.00Medium
3/27/2018Cantor FitzgeraldSet TargetBuy$20.00High
3/22/2018SVB LeerinkReiterated RatingOutperformLow
3/6/2018Needham & Company LLCLower TargetBuy$43.00 ➝ $19.00High
3/6/2018GuggenheimDowngradeBuy ➝ NeutralHigh
3/5/2018Cantor FitzgeraldSet TargetBuy$20.00N/A
3/5/2018MizuhoDowngradeBuy ➝ NeutralN/A
3/5/2018CowenSet TargetBuy$25.00N/A
2/23/2018MizuhoReiterated RatingBuyLow
2/22/2018Cantor FitzgeraldSet TargetBuy$45.00High
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.88 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/11/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/10/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/10/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
12/9/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/8/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/7/2023

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Dermira logo
Dermira, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older. It also develops lebrikizumab, a novel injectable humanized monoclonal antibody targeting interleukin 13 that is in Phase IIb clinical trial for the treatment of moderate-to-severe atopic dermatitis; and early-stage research and development programs in other areas of dermatology. Dermira, Inc. has a right of first negotiation agreement with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate for the treatment of hyperhidrosis in Japan; an agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab; and a development and commercialization agreement with UCB Pharma S.A. to develop Cimzia for the treatment of psoriasis. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $2.15
Low: $2.07
High: $2.43

50 Day Range

MA: $18.75
Low: $18.73
High: $18.85

52 Week Range

Now: $2.15
Low: $5.25
High: $19.48

Volume

44,632 shs

Average Volume

41,493 shs

Market Capitalization

$38.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.35

Frequently Asked Questions

What sell-side analysts currently cover shares of Dermira?

The following sell-side analysts have issued research reports on Dermira in the last twelve months: B. Riley, and Cantor Fitzgerald.
View the latest analyst ratings for DERM.

What is the current price target for Dermira?

1 Wall Street analysts have set twelve-month price targets for Dermira in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 390.2%. B. Riley has the highest price target set, predicting DERM will reach $10.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $10.00 for Dermira in the next year.
View the latest price targets for DERM.

What is the current consensus analyst rating for Dermira?

Dermira currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DERM will outperform the market and that investors should add to their positions of Dermira.
View the latest ratings for DERM.

What other companies compete with Dermira?

How do I contact Dermira's investor relations team?

Dermira's physical mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company's listed phone number is 650-421-7200 and its investor relations email address is [email protected] The official website for Dermira is www.dermira.com. Learn More about contacing Dermira investor relations.